Amgen Inc (AMGN)
Exchange: NASDAQ
Currency: USD
Price: 0.00 ()
Summary
| 52 Week range | 200d Moving Avg. | Beta |
| 0.00 – 0.00 | 0.00 | 0.00 |
| Dividend | Dividend Yield | Ex-Dividend date |
| 0.00 | 0.00% | 0000-00-00 |
| P/E Ratio | Latest EPS | DGR 3 years |
| 22.98 | 0.00 | 10.06% |
Overvalued
Low
N.A.
High
Slow
Dividend Growth
Fast
Profile
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease. It also markets other products in various markets, including Nplate, Vectibix, Repatha, Parsabiv, BLINCYTO, Aimovig, NEUPOGEN, Otezla, AMGEVITA, KANJINTI, EVENITY, IMLYGIC, MVASI, and Corlanor. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; QIAGEN N.V.; Adaptive Biotechnologies; and Eli Lilly and Company. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
| Sector: | Industry: | |
| Healthcare | Drug Manufacturers—General | |
Total ESG Score
21 – 24 percentile
Environment
2 – 3 percentile
Social
15 – 3 percentile
Governance
6 – 3 percentile
Controversy level
2
MSCI ESG-Rating
AA
see MSCI ESG rating explained
Dividend Safety Metrics
| Latest EPS | 0.00 | |
| Annual Payout | 0.00 | |
| Payout Ratio | 0.00% | |
| Dividend growth | 0 Years | |
| Dividend Score | 0 | |
| Dividend Coverage Ratio | 0.00 | |
| Altman-Z score | 0.00 |
Amgen Inc (AMGN) Valuation
Amgen Inc current dividend yield of 0.00% is -100% below its 5-year average. The 5-year average dividend yield is 2.74% (see red-line in chart). This indicates the stock looks overvalued today.
Amgen Inc (AMGN) Performance
The chart below displays the total price return(%) of Amgen Inc for different periods:
Amgen Inc (AMGN) Total Return
The chart below displays the (CAGR) total return (%) including all dividends paid of Amgen Inc for different periods:
Dividend Scorecard
| Dividend Yield (TTM) | Annual Payout | Payout Ratio | Dividend growth |
| 0.00 | 0.00 | 0.00% | 0 Years |
Dividend Growth Summary
| 3 Year Growth Rate (CAGR) | 10.06% |
| 5 Year Growth Rate (CAGR) | 11.97% |
| 10 Year Growth Rate (CAGR) | 28.81% |
Dividend Growth Rates History
| Year | Payout Amount | Annual Payout Growth (YoY) |
|---|---|---|
| 2022 | 3.880 | -44.9% |
| 2021 | 7.040 | 10.0% |
| 2020 | 6.400 | 10.3% |
| 2019 | 5.800 | 9.8% |
| 2018 | 5.280 | 14.8% |
| 2017 | 4.600 | 15.0% |
| 2016 | 4.000 | 26.6% |
| 2015 | 3.160 | 29.5% |
| 2014 | 2.440 | 29.8% |
| 2013 | 1.880 | 30.6% |
| 2012 | 1.440 | 157.1% |
| 2011 | 0.560 | 279,900.0% |
Amgen Inc (AMGN) Dividend Payment History